T-cell Acute Lymphoblastic Leukemia
Onechain Immunotherapeutics S.L. focuses on clinical research in T-cell Acute Lymphoblastic Leukemia, with particular attention to relapsed and refractory disease and CD1a-positive patient populations.
- Relapsed and refractory T-ALL
- CD1a-positive leukemia
- CAR-T cell therapy
Its research activity in this field is centered on immunotherapy for difficult-to-treat haematological malignancies.
T-cell Acute Lymphoblastic Lymphoma
The sponsor also studies T-cell acute lymphoblastic lymphoma, including patients with relapsed or refractory disease who may have limited treatment options.
- Relapsed and refractory T-ALL/LL
- CD1a-targeted therapy
- Leukaemia-lymphoma overlap
This area reflects a therapeutic interest in aggressive lymphoid cancers and cell-based oncology treatments.
CAR-T Cell Therapy
Clinical work funded by the sponsor includes CAR-T cell therapy using hCD1a-CAR T approaches for patients with relapsed/refractory disease.
- hCD1a-CAR T cells
- OC-1 cells
- Immune cell engineering
The therapeutic emphasis is on targeted cellular immunotherapy for T-lineage malignancies.
Long-term Safety Monitoring
Another key area of interest is extended follow-up after CAR-T infusion, with monitoring for delayed adverse events in patients previously treated for T-ALL/LL.
- Delayed adverse events
- Post-infusion surveillance
- Long-term patient monitoring
This work supports ongoing evaluation of safety in advanced immuno-oncology settings.
